Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 3/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417563 | 0.87 | KMT2A (0.56) | GAATRPA1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1477123 | 0.84 | GRM5 (0.48) | GAAGRM5TRPA1VNN1PIK3CA | |
| SCHEMBL1692766 | 0.83 | GRM5 (0.49) | GRM5TRPA1VNN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20812515 | 0.83 | GRM5 (0.46) | GRM5TRPA1VNN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL19249058 | 0.83 | TRPA1 (0.57) | GAAGRM5TRPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17489498 | 0.81 | EGLN1 (0.43) | GRM5ALDH1A1TMPRSS4PKM | |
| SCHEMBL7213897 | 0.81 | GRM5 (0.46) | GAAGRM5TRPA1VNN1ALDH1A1 | |
| SCHEMBL30200709 | 0.80 | GRM5 (0.46) | GAAGRM5TRPA1VNN1ALDH1A1 | |
| SCHEMBL2033094 | 0.80 | BRAF (0.42) | GAAALDH1A1MEN1KMT2ATMPRSS4 | |
| SCHEMBL3820471 | 0.80 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2TMPRSS4MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-114206870-B | Tricyclic AKR1C 3-dependent KARS inhibitors | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | NOVARTIS AG (CH) | 2024-04-30 | — | — | US | disclosed |
| EP-4349839-A2 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4013500-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114206870-A | Tricyclic AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021005586-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2021-01-14 | — | — | WO | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | GAA 541/4885GRM5 2894/4885TRPA1 4355/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | GAA 924/4885GRM5 622/4885TRPA1 2838/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | GAA 541/4885GRM5 2894/4885TRPA1 4355/4885 |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | AKR1C2, AKR1B1, AKR1C1 | GAA 541/4885GRM5 2894/4885TRPA1 4355/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | GAA 924/4885GRM5 622/4885TRPA1 2838/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | GAA 541/4885GRM5 2894/4885TRPA1 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.